Page last updated: 2024-09-03

gefitinib and cyclin d1

gefitinib has been researched along with cyclin d1 in 19 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(cyclin d1)
Trials
(cyclin d1)
Recent Studies (post-2010) (cyclin d1)
5,2315662,91910,885705,157

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (31.58)29.6817
2010's10 (52.63)24.3611
2020's3 (15.79)2.80

Authors

AuthorsStudies
Cole, IE; Gallagher, RM; Kalish, LH; Kwong, RA; Musgrove, EA; Sutherland, RL1
Adam, L; Bar-Eli, M; Brown, G; Diehl, AJ; Dinney, CP; Kassouf, W; McConkey, DJ1
Bissonnette, M; Cerda, S; Cohen, G; Dougherty, U; Fichera, A; Gong, C; Hart, J; Jagadeeswaran, S; Joseph, L; Khare, S; Little, N; Mustafi, R; Sehdev, A; Tallerico, M; Tretiakova, M; Turner, JR; Yuan, W1
Garber, K1
Ferlini, C; Mozzetti, S; Riccardi, A; Riccardi, R; Servidei, T1
Bayer-Zubek, V; Cordon-Cardo, C; Costa, J; Donovan, MJ; Greco, FA; Hainsworth, JD; Kotsianti, A; Parums, DV; Teverovskiy, M; Verbel, D1
Bhattacharyya, A; Kundu, S; Sengupta, S1
Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H1
Chen, SC; Chiou, SJ; Chuang, LY; Guh, JY; Hwang, CC; Ko, YM; Lin, TD1
Choi, JW; Jeong, Y; Jung, SH; Kim, HW; Kim, J; Park, KH; Wairagu, PM; Yeh, BI; Yong, SJ1
Izumi, H; Kuwano, M; Maeda, M; Murakami, Y; Ono, M; Watari, K1
Aderhold, C; Erben, P; Faber, A; Hoermann, K; Hofheinz, RD; Schultz, JD; Umbreit, C; Weiss, C; Wenzel, A1
Imai, S; Koyama, S; Matsubara, K; Nakagawa, S; Nakagawa, T; Omura, T; Yano, I; Yonezawa, A1
Emons, G; Girgert, R; Gründker, C1
Chen, JY; Jiang, Z; Long, F; Ren, YG; Tang, JC; Zhao, J1
Bi, F; Dai, XY; Gong, QY; Liu, BS; Nie, YZ; Tang, QL; Xia, HW; Xu, HJ1
Cao, J; Liao, X; Liu, L; Mei, S; Shuai, S; Wang, H; Wang, S1
Deng, YJ; Du, ZQ; Shan, KZ; Yang, SF; Yue, PY1
Hou, M; Huang, L; Li, Y; Liu, J; Shen, W; Zhou, Q1

Trials

1 trial(s) available for gefitinib and cyclin d1

ArticleYear
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
    Breast cancer research and treatment, 2011, Volume: 129, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles

2011

Other Studies

18 other study(ies) available for gefitinib and cyclin d1

ArticleYear
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Antineoplastic Agents; Blotting, Southern; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Prognosis; Protein Kinase Inhibitors; Quinazolines; S Phase; Time Factors

2004
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
    Cancer research, 2005, Nov-15, Volume: 65, Issue:22

    Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Growth Processes; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Induction; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Platelet-Derived Growth Factor; Urinary Bladder Neoplasms

2005
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
    Cancer research, 2007, Jan-15, Volume: 67, Issue:2

    Topics: Adenoma; Animals; Azoxymethane; beta Catenin; Carcinogens; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, ras; Male; Mice; Mice, Inbred A; Mutation; Quinazolines; Signal Transduction; Up-Regulation

2007
New insights into oncogene addiction found.
    Journal of the National Cancer Institute, 2007, Feb-21, Volume: 99, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab

2007
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    International journal of cancer, 2008, Dec-15, Volume: 123, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin D1; DNA, Complementary; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, DNA; Signal Transduction

2008
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:8

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cyclin D1; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines; Survival Rate

2009
EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride.
    Inhalation toxicology, 2011, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Cadmium Chloride; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Environmental Pollutants; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lethal Dose 50; Lung Neoplasms; Microscopy, Acoustic; Proliferating Cell Nuclear Antigen; Quinazolines; Up-Regulation

2011
Gefitinib attenuates transforming growth factor-β1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells.
    Translational research : the journal of laboratory and clinical medicine, 2011, Volume: 158, Issue:4

    Topics: Animals; Benzamides; Cell Line; Collagen; Cyclin D1; Dioxoles; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Flavonoids; Gefitinib; Imidazoles; Kidney; MAP Kinase Signaling System; Mice; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Quinazolines; Rats; Receptors, Transforming Growth Factor beta; Smad Proteins; Transforming Growth Factor beta1; Translational Research, Biomedical

2011
Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer.
    Biochemical and biophysical research communications, 2014, May-09, Volume: 447, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin B; Cyclin D1; ErbB Receptors; Gefitinib; Humans; Hydrocarbons, Fluorinated; Indoles; Liver X Receptors; Lung Neoplasms; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Quinazolines; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Sulfones

2014
CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
    Lung cancer (Amsterdam, Netherlands), 2015, Volume: 87, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; CpG Islands; Cyclin D1; DNA Methylation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines

2015
MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.
    Anticancer research, 2015, Volume: 35, Issue:7

    Topics: Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Epigenesis, Genetic; ErbB Receptors; Gefitinib; Human papillomavirus 16; Humans; Lapatinib; Matrix Metalloproteinase 9; Quinazolines; Vimentin

2015
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclin D1; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-2; Gefitinib; Humans; Lung Diseases, Interstitial; Phosphorylation; Pulmonary Alveoli; Quinazolines; Signal Transduction; Taurochenodeoxycholic Acid

2015
17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
    Oncology reports, 2017, Volume: 37, Issue:2

    Topics: Antineoplastic Agents; Aromatase; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclin D1; ErbB Receptors; Estradiol; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Phosphorylation; Quinazolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; src-Family Kinases; Triple Negative Breast Neoplasms

2017
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
    Life sciences, 2018, Jul-01, Volume: 204

    Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Naphthoquinones; Quinazolines; Signal Transduction; Sincalide; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones

2018
Geranylgeranyl transferase 1 inhibitor GGTI‑298 enhances the anticancer effect of gefitinib.
    Molecular medicine reports, 2018, Volume: 18, Issue:4

    Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Phosphorylation; Proto-Oncogene Proteins c-akt; rhoA GTP-Binding Protein; Signal Transduction

2018
TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
    Cancer science, 2021, Volume: 112, Issue:10

    Topics: Acetyltransferases; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cyclin D1; Cytoplasm; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lysosomes; MAP Kinase Kinase 1; Mice; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Transcription Factors; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays

2021
E2F1-induced long non-coding RNA MCF2L-AS1 modulates Cyclin D1 mRNA stability through ELAVL1 to induce Gefitinib resistance in non-small cell lung cancer.
    Acta biochimica Polonica, 2022, Oct-18, Volume: 69, Issue:4

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin D1; E2F1 Transcription Factor; ELAV-Like Protein 1; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; RNA Stability; RNA, Long Noncoding

2022
[STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022, Nov-20, Volume: 25, Issue:11

    Topics: Adenocarcinoma of Lung; Animals; Carcinoma, Non-Small-Cell Lung; Caspase 8; Caspase 9; Cyclin D1; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt

2022